Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 165 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03934372 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Incyte Biosciences International SàrlINDUSTRY | 7 | Jul 23, 2026 | clinicaltrials |
| NCT05719558 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | recruiting | Phase 1 | 798 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05836324 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 570 | Incyte CorporationINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT06234098 | Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Alyssum TherapeuticsINDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06545942 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 220 | MOMA TherapeuticsINDUSTRY | 3 | Jul 23, 2026 | clinicaltrials |
| NCT06719362 | A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies | recruiting | Phase 1 | 110 | Providence Health & ServicesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | recruiting | Phase 1 | 56 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06974110 | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 132 | MOMA TherapeuticsINDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07374848 | Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors | recruiting | Phase 1 | 180 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07589205 | Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors | recruiting | Phase 1 | 493 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | recruiting | Phase 1 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06179160 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | recruiting | Phase 1 | 710 | Incyte CorporationINDUSTRY | 8 | Jul 22, 2026 | clinicaltrials |
| NCT06721689 | PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors(PEEL-224) | recruiting | Phase 1 / Phase 2 | 59 | Theodore LaetschOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07524322 | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors | recruiting | Phase 1 | 63 | Regor Pharmaceuticals Inc.INDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05098132 | Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers(SYNERGY-101) | recruiting | Phase 1 / Phase 2 | 364 | SynthekineINDUSTRY | 4 | Jul 21, 2026 | clinicaltrials |
| NCT06687070 | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST | recruiting | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07368127 | A Study of TPD3310 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 112 | TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05092373 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | recruiting | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07189195 | TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma | recruiting | Phase 1 | 52 | University of California, DavisOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03819296 | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer | recruiting | Phase 1 | 800 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05053971 | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06265688 | First In Human Study of CX-2051 in Advanced Solid Tumors | recruiting | Phase 1 | 160 | CytomX TherapeuticsINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06587295 | Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy | recruiting | Phase 1 | 40 | National Cancer Centre, SingaporeOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06657144 | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 154 | Coherus Oncology, Inc.INDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 361 | ModernaTX, Inc.INDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT07702162 | A Clinical Study of PA5 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 49 | Chongqing Peg-Bio Biopharm Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07137416 | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer | recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06997029 | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 234 | Bristol-Myers SquibbINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07617493 | Evaluation of ICP-B208 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 539 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06625593 | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 168 | BeOne MedicinesINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT06874335 | A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | recruiting | Phase 1 | 140 | Biohaven Therapeutics Ltd.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07691775 | A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Heron Neutron Medical Corp.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06320405 | Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 38 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06888830 | A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour | recruiting | Phase 1 / Phase 2 | 374 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05768139 | First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors(PIKALO-1) | recruiting | Phase 1 / Phase 2 | 880 | Eli Lilly and CompanyINDUSTRY | 9 | Jul 7, 2026 | clinicaltrials |
| NCT07337525 | A First in Human Study of PLT012 in Participants With Solid Tumor Cancers | recruiting | Phase 1 | 36 | Pilatus Biosciences IncINDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT06043713 | Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations | recruiting | Phase 1 | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07300150 | A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors | recruiting | Phase 1 | 210 | PAQ Therapeutics, Inc.INDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT07664150 | CW-301 FIH Study of CAN016 | recruiting | Phase 1 / Phase 2 | 90 | Canwell Biotech LimitedINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05170958 | A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 396 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05720117 | A Study of PYX-201 in Advanced Solid Tumors | recruiting | Phase 1 | 330 | Pyxis Oncology, IncINDUSTRY | 4 | Jun 30, 2026 | clinicaltrials |
| NCT07140393 | A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor | recruiting | Phase 1 / Phase 2 | 120 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07508761 | IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 52 | Nanjing Immunophage Biotech Co., LtdINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05861895 | HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors | recruiting | Phase 1 | 84 | HighField Biopharmaceuticals CorporationINDUSTRY | 2 | Jun 26, 2026 | clinicaltrials |
| NCT07606612 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 31 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04219254 | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 197 | BioInvent International ABINDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT06220864 | SNV1521 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 400 | Synnovation Therapeutics, Inc.INDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT06352359 | Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors | recruiting | Phase 1 | 72 | OncoC4, Inc.INDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2026source: clinicaltrials